Enoticumab (REGN421, SAR153192) is a monoclonal antibody of the IgG1κ subtype designed to specifically target human Delta-like ligand 4 (DLL4). DLL4 is an integral component of the Notch signaling pathway, which is known to influence a variety of cellular processes including the regulation of fatty acid uptake via non-transcriptional modulation of macropinocytosis-dependent mechanisms. This antibody has demonstrated significant efficacy in preclinical studies, particularly in models of ovarian cancer. Administration of Enoticumab at a dosage of 2.5 mg/kg once weekly led to tumor growth inhibition rates of 86% in subcutaneous TOV-112D and 83% in intraperitoneal A2780 human tumor xenograft models. These findings underscore its potential utility in therapeutic applications targeting DLL4-mediated pathways.
Enoticumab (REGN421, SAR153192) is a monoclonal antibody of the IgG1κ subtype designed to specifically target human Delta-like ligand 4 (DLL4). DLL4 is an integral component of the Notch signaling pathway, which is known to influence a variety of cellular processes including the regulation of fatty acid uptake via non-transcriptional modulation of macropinocytosis-dependent mechanisms. This antibody has demonstrated significant efficacy in preclinical studies, particularly in models of ovarian cancer. Administration of Enoticumab at a dosage of 2.5 mg/kg once weekly led to tumor growth inhibition rates of 86% in subcutaneous TOV-112D and 83% in intraperitoneal A2780 human tumor xenograft models. These findings underscore its potential utility in therapeutic applications targeting DLL4-mediated pathways.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
